Abstract
Background: The Ewing sarcoma (ES) represents 10 to 15% malignant bone tumors and 40 to 45% pediatric malignant bone tumors. The aim of this review is to clarify the therapeutic results and prognostic factors of this entity.
Methods: A systematic review of the literature was performed. Studies focused on the management of ES were considered for inclusion. Result: ES represents a model of multidisciplinary approach. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between the pediatric and medical oncologists. The overall 5- year survival of Ewing localized tumors was 70% versus 30% in metastatic ES. Conclusion: The treatment of ES includes neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The role of high-dose chemotherapy is still debated.Keywords: Chemotherapy, ewing sarcoma, malignant bone tumors, prognostic factor, therapeutic strategies, treatment.
Reviews on Recent Clinical Trials
Title:A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?
Volume: 12 Issue: 1
Author(s): Wala Ben Kridis, Nabil Toumi, Hadil Chaari, Afef Khanfir, Kamel Ayadi, Hassib Keskes, Tahia Boudawara, Jamel Daoud and Mounir Frikha
Affiliation:
Keywords: Chemotherapy, ewing sarcoma, malignant bone tumors, prognostic factor, therapeutic strategies, treatment.
Abstract: Background: The Ewing sarcoma (ES) represents 10 to 15% malignant bone tumors and 40 to 45% pediatric malignant bone tumors. The aim of this review is to clarify the therapeutic results and prognostic factors of this entity.
Methods: A systematic review of the literature was performed. Studies focused on the management of ES were considered for inclusion. Result: ES represents a model of multidisciplinary approach. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between the pediatric and medical oncologists. The overall 5- year survival of Ewing localized tumors was 70% versus 30% in metastatic ES. Conclusion: The treatment of ES includes neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The role of high-dose chemotherapy is still debated.Export Options
About this article
Cite this article as:
Kridis Ben Wala, Toumi Nabil, Chaari Hadil, Khanfir Afef, Ayadi Kamel, Keskes Hassib, Boudawara Tahia, Daoud Jamel and Frikha Mounir, A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?, Reviews on Recent Clinical Trials 2017; 12 (1) . https://dx.doi.org/10.2174/1574887112666170120100147
DOI https://dx.doi.org/10.2174/1574887112666170120100147 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aging and immunopathology in primary Sjögren's syndrome
Current Aging Science Multidisciplinary Treatment of Early Stage Endometrial Cancer
Anti-Cancer Agents in Medicinal Chemistry Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry Sydnones: A Brief Review
Mini-Reviews in Medicinal Chemistry 5-Fluorouracil Derivatives Induce Differentiation Mediated by Tubulin and HLA Class I Modulation
Medicinal Chemistry The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Gold Coordination Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment
Current Pharmaceutical Design T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Recent Advances in Active Hepatic Targeting Drug Delivery System
Current Drug Targets Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells
Current Cancer Drug Targets The Endeavours in RAS Inhibition - the Past, Present, and Future
Current Topics in Medicinal Chemistry Exploring Protein-Protein and Protein-Ligand Interactions in the Immune System using Molecular Dynamics and Continuum Electrostatics
Current Physical Chemistry The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101
Anti-Cancer Agents in Medicinal Chemistry Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma
Anti-Cancer Agents in Medicinal Chemistry Drug Targets in Cytomegalovirus Infection
Infectious Disorders - Drug Targets